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Background: Cell migration is an integral component of intimal hyperplasia development and proteases are pivotal in the
process. Understanding the role of urokinase signaling within the cells of vasculature remains poorly defined. The study
examines the role of amino-terminal fragment (ATF) of urokinase on a pivotal cross-talk receptor, epidermal growth factor
receptor (EGFR). EGFR is transactivated by both G-protein-coupled receptors and receptor tyrosine kinases and is key to
many of their responses. We hypothesize that A Disintegrin andMetalloproteinase Domains (ADAM) allows the transactiva-
tion of EGFR by ATF.
Objective: To determine the role of ADAM in EGFR transactivation by ATF in human vascular smooth muscle cells
(VSMC) during cell migration.
Methods:Human coronary VSMCwere cultured in vitro. Assays of EGFR phosphorylationwere examined in response to ATF
(10 nM) in the presence and absence of thematrixmetalloprotease (MMP) inhibitor GM6001, the ADAM inhibitors TAPI-0
and TAPI-1, heparin binding epidermal growth factor (HB-EGF) inhibitor, CRM197, HB-EGF inhibitory antibodies,
epidermal growth factor (EGF) inhibitory antibodies, and the EGFR inhibitor AG1478. The small interference ribonucleic acid
(siRNA) against EGFR and ADAM-9, ADAM-10, ADAM-12, and adenoviral delivered Gbg inhibitor, ARKCT were also used.
Results: ATF produced concentration-dependent VSMC migration (by wound assay and Boyden chamber), which was
inhibited by increasing concentrations of AG1478. ATFwas shown to induce time-dependent EGFR phosphorylation, which
peaked at fourfold greater than control. Pre-incubation with the G inhibitor ARKCT inhibited EGFR activation by ATF.
This migratory and EGFR response was inhibited by AG1478 in a concentration-dependent manner. Incubation with siRNA
against EGFR blocked the ATF-mediated migratory and EGFR responses. EGFR phosphorylation by ATF was blocked by
inhibition ofMMP activity and the ligandHB-EGF. The presence of the ADAM inhibitors, TAPI-0 and TAPI-1 significantly
decreased EGFR activation. EGFR phosphorylation by EGF was not interrupted by inhibition of MMP, ADAMs, or
HB-EGF.Direct blockade of the EGFRprevented activation by bothATF andEGF. Incubationwith siRNA toADAM-9 and
-10 significantly reduced HB-EGF release from VSMC and EGFR activation in response to ATF. The siRNA against
ADAM-12 had no effect.
Conclusion: ATF can induce transactivation of EGFR by an ADAM-mediated, HB-EGF-dependent process. Targeting a
pivotal cross-talk receptor such as EGFR is an attractive molecular target to inhibit cell migration. (J Vasc Surg 2009;49:
1296-303.)
Clinical Relevance: Cell migration is an integral component of intimal hyperplasia development and proteases are pivotal in
the process. Understanding the role of urokinase signaling within the cells of vasculature remains poorly defined. The study
examines the role of ATF of urokinase on a pivotal cross-talk receptor, EGFR. EGFR is transactivated by both G-protein-
coupled receptors and receptor tyrosine kinases and is key tomany of their responses. ATF can induce transactivation of EGFR
by an ADAM-mediated, HB-EGF-dependent process. Targeting a pivotal cross-talk receptor such as EGFR, which can be
transactivated by both G-protein-coupled receptors and receptor tyrosine kinases is an attractive molecular target.From the Vascular Biology and Therapeutics Program, Methodist DeBakey
Heart and Vascular Center, Department of Cardiovascular Surgery, The
Methodist Hospital, and The Methodist Hospital Research Institute,
Houston, Tex.
The study was supported by the U.S. Public Health Service HL086968 and
HL67746 awarded to Dr Mark G. Davies.
Competition of interest: none.
Reprint requests: Mark G. Davies, MD, PhD, MBA, Methodist DeBakey
Heart and Vascular Center, Department of Cardiovascular Surgery, The
Methodist Hospital, 6550 Fannin, Smith Tower - Suite 1401, Houston,
TX 77030 (e-mail: mdavies@tmhs.org).
0741-5214/$36.00
Copyright © 2009 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2008.12.026
1296Vessels remodel during atherogenesis in response to
altered flow and following injury. This remodeling has been
shown to involve an integrative program of cell prolifera-
tion, migration, and extracellular matrix modulation.1 The
migration of vascular smoothmuscle cells (VSMC) involves
the complex regulation of proteases, integrins, and extra-
cellular molecules leading to the sequence of attachment,
detachment, and contraction events, which allow a cell to
move through the extracellular matrix. Urokinase plasmin-
ogen activator (uPA) is a serine protease that is the primary
plasminogen activator in tissue remodeling processes and
increased serum uPA is associated with development of
restenosis after coronary angioplasty.2 In addition to its
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mediating cell signaling. Plasminogen activation is a com-
plex system at the level of the cellular microenvironment.3
The uPA is primarily responsible for plasmin generation in
tissue remodeling processes, and is localized to the mem-
brane by its receptor, uPAR.4 The uPA induces cell migra-
tion through urokinase plasminogen activator receptor
(uPAR) and it appears to be receptor-initiated and G-
protein mediated; migration is dependent on ERK1/2
activity. The uPAR is involved in a multi-protein complex
containing integrins, low-density lipoprotein (LDL)-
related protein (LRP), FPRL1 (a G-protein coupled recep-
tor [GPCR]) and epidermal growth factor receptor
(EGFR).5 Interaction with the components of the complex
may allow differential cell signaling. EGFR is transactivated
by both GPCRs and receptor-linked tyrosine kinases and is
the key to many of their responses. The uPA induces time-
dependent phosphorylation of the EGFR.6 Inhibition of
EGFR reduces ERK1/2 activation and cell migration.6
However, uPA is composed of three domains: amino-
terminal fragment (ATF), kringle (K), and carboxyterminal
(CTF) fragments, each of which is distinct and biologically
active. The ATF and K fragments mediate VSMC migra-
tion.7,8 With respect to ATF, the response is due to binding
and cleavage of uPAR into a cell-bound D1 and a soluble
D2/D3 fragment. The D2/D3 then binds to the low affinity
receptor of fMPL, FPRL1, to induce a Gi-mediated re-
sponse.9 We have shown that ATF can strongly induce
plasmin-independent VSMC migration in vitro,10 which is
both PI3K-ERK1/2 and PI3K-akt dependent.11 This mi-
gration can be blocked by inhibition of EGFR. At present,
the triple membrane passing signaling (TMPS) mecha-
nism of GPCR-induced EGFR activation is a widely
accepted model of EGFR transactivation.12-14 In the
TMPS model, there is a sequence of three transmembrane
signaling events: GPCR activation followed by transmem-
brane matrix metalloprotease (MMP) activation, and sub-
sequent activation of the EGFR by release of heparin bind-
ing epidermal growth factor (HB-EGF), a tethered ligand
of the EGFR. A potential transmembrane protease system
that would convey a signal from intracellular domain to the
extracellular domain is the A Disintegrin and Metallopro-
teinase Domains (ADAM) proteases, which span the mem-
brane and can be activated intracellularly to mediate an
extracellular MMP action (Fig 1). We hypothesize that
ADAM allows the transactivation of EGFR by ATF. This
study seeks to determine the role of ADAM in EGFR
transactivation by ATF in human VSMC during cell migra-
tion.
METHODS
Experimental design. Human VSMC (passages 3-6,
Clontech) were cultured in vitro. Lineage was confirmed by
a-actin Western blotting. Assays of EGFR phosphorylation
were examined in response to ATF in the presence and
absence of theMMP inhibitor GM6001, the ADAM inhib-
itors TAPI-0 and TAPI-1, HB-EGF inhibitor, CRM197,
HB-EGF inhibitory antibodies, EGF inhibitory antibodiesand the EGFR inhibitor AG1478. Chemical inhibitors and
antibodies were incubated for 1 hr before treatment. siRNA
against EGFR and ADAM-9, ADAM-10, and ADAM-12
were also used.
MATERIALS
ATF was purchased from American Diagnostica, Inc
(Greenwich, Conn). The EGF heparin was purchased from
Sigma Chemical Co (St Louis, Mo). AG1478 and CRM197
were purchased from Calbiochem (La Jolla, Calif). GM6001
was purchased fromChemicon International, Inc (Temecula,
Calif). CRM197, TAPI-0, and TAPI-1 were purchased from
Biomol (Plymouth Meeting, Pa). The Anti-HB-EGF anti-
body was purchased from R&D Systems, Inc (Minneapolis,
Minn). The anti-EGFR antibody (151-IgG) developed byDr
Ann Hubbard was obtained from the Developmental Studies
Hybridoma Bank, developed under the auspices of the Na-
tional Institute of Child Health and Human Development
and maintained by The University of Iowa (Department of
Biological Sciences, Iowa City, Iowa). The siRNA sequences
for ADAMs were as follows: ADAM-9, AAUCACUGUG-
GAGACAUUUGCdTdT and AAACUUCC AGUGUGU-
AGAUGCdTdT; ADAM-10, AAUGAAGAGGGACACU-
UCCCUdTdT and AAGUUGCCUCCUCCUAAACCAd-
TdT; and ADAM-1, AACCUCGCUGCAAAGAAUGU-
GdTdT and AAGACCUUGATACGACUGCUGdTdT.
Peroxidase-conjugated antirabbit IgG antibody (raised in
goat) and peroxidase-conjugated antimouse IgG antibody
(raised in goat) were purchased from Jackson Immuno
Research Laboratories, Inc (West Grove, Pa). Phospho-
EGFR (Y1068), total EGFR antibodies were obtained
from Cell Signaling Technology, Inc (Beverley, Mass).
Fig 1. Proposed triple membrane passing system for amino-
terminal fragment urokinase (ATF). ATF binds urokinase plasmin-
ogen activator receptor (uPAR) and this activates G and other
intracellular molecules to activate A Disintegrin And Metallopro-
teinase Domains (ADAM) protease. Activation of ADAM associ-
ated matrix metalloproteinase (MMP) activity leads to release of
the tethered ligand, heparin binding epidermal growth factor
(HB-EGF), which in turn activates the epidermal growth factor
receptor (EGFR). Activation of EGFR is necessary for ATF medi-
ated migration.Dulbecco modified Eagle minimal essential medium
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purchased from Mediatech (Herndon, Va).
Boyden chamber. Chemotaxis was measured using a
48-well Boyden chamber (Neuroprobe Inc, Gaithersburg,
Md) and polycarbonate filters (Neuroprobe Inc, 10 m
pore size, 25 80mm, PVP free) with VSMC as previously
described.6,10 ATF (10 nM) was added to the lower wells.
Trials included 8 or 12 wells per reagent per trial, and were
repeated no fewer than three times.
Western blotting. Cells were allowed to grow to 80%
confluence and starved for 48 hours. Cells were then stim-
ulated with ATF (10 nM) or EGF (10 nM) alone and in the
presence of pharmacological and peptide inhibitors; cells
were harvested at time points from 0 to 30 minutes. West-
ern blotting was performed as previously described.15
siRNA transfection. Pre-designed HPCL purified
siRNA for gene knockdown for EGFR or control siRNA
was purchased from Santa Cruz Biotechnology (Santa
Cruz, Calif) and ADAM-9, ADAM-10, and ADAM-12
proteins from Ambion Inc (Austin, Tex). VSMC of 50%
confluence in 60 mm plates are starved overnight in 4 mL
Opti-MEM reduced serum medium (Gibco, Langley,
Okla). The siRNA is transfected using Lipofectamine 2000
(Invitrogen, Inc, Carlsbad, Calif) following product proto-
col. Briefly, 22 l of Lipofectamine 2000 is first incubated
in total volume of 250 l of Opti-MEM for 5 minutes at
room temperature. It is then added to 250 l of Opti-
MEM containing 440 pmoles of siRNA. The solution is
mixed gently and incubated for 20 minutes at room tem-
perature, after which it is added to the starved plates. The
medium can be changed after 4-6 hours of incubation. The
cells may now be used between 24-72 hours after trans-
fection for EGFR assays. Scrambled siRNA served as a
control. Using themethodologies described, we conducted
concentration-dependent experiments with siRNA against
EGFR, ADAM-9, ADAM-10, and ADAM-12 and demon-
strated a concentration-dependent decrease in protein ex-
pression that was specific for the protein targeted without
altering the expression of the other proteins.
Adenoviral infection. Adenoviral vectors were con-
structed by Welgen, Inc (Worcester, Mass) using purified
plasmid encoding ARKCT, obtained from Guthrie cDNA
Resource center. VSMC were plated at 70% confluence in
100 mm dishes and allowed to grow overnight. Recombi-
nant adenovirus was then added at the appropriate concen-
trations (ARKCT; 100 MOI) in a reduced volume of
media (1.5-2mL). After 48 hour incubation, themedia was
changed and cells grown for an additional 24 hours. The
cells were then used for EGFR assays. Empty vector served
as control.
Measurement of tethered ligand HB-EGF. Cultured
VSMC were deprived of serum for 24 hours and then
cultured in phenol red-free Dulbecco’s modified Eagle’s
medium H21. Following exposure to ATF (10 nM) alone
and in the presence of pharmacological inhibitors, siRNA,
and adenoviral agents, medium was collected and concen-
trated using a Centricon centrifugal filter device (YM-3,
Millipore, Billerica, Mass). Samples were centrifuged at6500 g for at least 3 hours until volumewas reduced from
4 to 0.5 mL. Concentrates were incubated with 2.5 g of
anti-HB-EGF antibody and protein A-agarose overnight at
4°C. Immunoprecipitates were washed three times, boiled,
and electrophoresed on 15% SDS-polyacrylamide gels. Us-
ing conventional Western immunoblotting techniques,
HB-EGF levels were assessed using goat polyclonal anti-
HB-EGF IgG and donkey anti-goat IgG.
Data and statistical analysis. All data are presented as
the mean  standard error of the mean (SEM) and statis-
tical differences between groups were tested with a Kruskal-
Wallis nonparametric test with post hoc Dunn’s multiple
comparison correction, where appropriate. A P value less
Fig 2. Amino-terminal (ATF) (10 nM) induces significant
smooth muscle cell migration in the Boyden chamber migration
assays. A, Migration in response to ATF was decreased in a
concentration-dependent manner by the epidermal growth factor
receptor (EGFR) inhibitor (AG1478, 1 hour pre-stimulation and
12 hours stimulation); (B) Pre-incubation (4-6 hours) with small
interference ribonucleic acid (siRNA) to EGFR inhibited the mi-
gratory response. Insert shows the efficacy of the siRNA in knock-
ing down the total EGFR protein present. Values are the mean 
SEM (n  6, **P  .01 compared to control).than .05 was regarded as significant.
wn ab
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To examine the effect of EGFR on ATF mediated
VSMC migration, we employed the Boyden chamber mi-
gration assay. ATF (10 nM) induced significant smooth
muscle cell migration (Fig 2). A similar response was noted
if hydroxyurea was added to prevent and control for prolif-
eration. This response to ATF was inhibited by increasing
concentrations of the EGFR inhibitor, AG1478, and by
application of siRNA against EGFR (Fig 2), suggesting
that EGFR plays a role in the pathways leading to ATF-
mediated cell migration. ATF induced a fourfold increase in
EGFR phosphorylation as determined by activation of
Y1068 phosphorylation site; the phosphorylation response
was inhibited in a concentration-dependent manner by
increasing concentrations of AG1478 (0.1-1000 nM) (Fig
Fig 3. A, Amino-terminal (ATF)-induced a fourfold inc
ylation and (B) this response was inhibited in a conce
AG1478 (0.1-1000 nM, 1 hour pre-stimulation). C, Pre
to EGFR inhibited EGFR activation in response to ATF a
Response to AG1478 is shown for comparison (D). T
ARKCT (GI) inhibited EGFR activation in response
factor (EGF). Values are the mean  SEM of the ra
unphosphosphorylated EGFR (n  6, *P  .05, **P
[DMEM] control). A representative Western blot is sho3,A and B). Pre-incubation with siRNA to EGFR inhibitedEGFR activation in response to ATF (Fig 3, C). ATF is
known to mediate its response through Gi G-proteins.10
Gi proteins are linked to G proteins, and G proteins
are known to be associated with triple membrane passing
system of tyrosine kinase-linked receptors such as EGFR.
To examine the role of G, we blocked G with the
inhibitor peptide ARKCT and showed that pre-incubation
with ARKCT inhibited EGFR activation by ATF (Fig 3,
D). No effect was seen with the empty vector or with EGF
application. When we pre-incubated VSMC with ARKCT
in the Boyden chamber, we saw an 85% decrease in migra-
tion in response to ATF (empty vector resulted in a 5%
decrease).
To determine if ATF activation of EGFR is via a trans-
activation mechanism, we examined the role of HB-EGF
in epidermal growth factor receptor (EGFR) phosphor-
on-dependent manner by increasing concentrations of
bation with small interference ribonucleic acid (siRNA)
so inhibited EGFR phosphorylation in response to EGF.
fection with adenovirus containing the G inhibitor
TF, but had no effect in response to epidermal growth
f the phosphorylation of EGFR relative to the total
1 compared to Dulbecco’s modified Eagle’s medium
ove the graphs.rease
ntrati
-incu
nd al
rans
to A
tio o
 .0on EGFR activation in response to ATF. EGFR phosphor-
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and by blockade of the ligand HB-EGF with the HB-EGF
inhibitor CRM197 (Fig 4). This suggests that HB-EGF is
involved and that it is being ligated by a protease, can bind
the EGFR extracellularly and induce EGFR phosphoryla-
tion. Incubation with an antibody against HB-EGF
blocked the ATF but not the EGF-mediated activation of
EGFR (Fig 4). Direct blockade of the EGFR with an
anti-EGFR antibody prevented activation by both ATF and
EGF (Fig 4). We tested whether plasmin had a role in ATF
signaling to EGFR. Blockade of metalloprotease activity
with the general inhibitor GM6001, at a level that inhibited
MMP-2/MMP-9 activity on gelatin zymography, did sig-
nificantly inhibit EGFR phosphorylation (Fig 5). EGFR
phosphorylation by EGF was not interrupted by the pres-
ence of inhibitors of plasmin or MMPs (Fig 5). Given the
fact that we demonstrated that intracellular processes
(G) and MMPs are involved, we tested whether ADAM
are involved. ADAMs span the membrane and can be
activated intracellularly to mediate an extracellular MMP
action. VSMC were incubated with the ADAM inhibitors
TAPI-0 (20 M) and TAPI-1 (10 M) and both blocked
EGFR activation by ATF but had no effect on EGFR
activation by EGF (Fig 5). The VSMC cells express
ADAM-9, ADAM-10, and ADAM-12. We examined their
contribution to EGFR activation by the use of siRNA to
ADAM-9, ADAM-10, and ADAM-12. The siRNA re-
duced ADAM-9, ADAM-10, ADAM-12 protein levels by
	50% (Fig 6). Incubation with siRNA ADAM-9 and
ADAM-10 significantly reduced EGFR activation in re-
Fig 4. Epidermal growth factor receptor (EGFR) phosphoryla-
tion by amino-terminal (ATF) (10 nM) was inhibited by pre-
incubation with heparin (100 U/mL), blockade of the ligand
heparin binding epidermal growth factor (HB-EGF) with the
HB-EGF inhibitor CRM197 and an Anti-HB-EGF antibody. IgG
had no effect. EGF-mediated activation of EGFR was not blocked
by these inhibitors. Direct blockade of the EGFR prevented acti-
vation by both ATF and EGF. Values are the mean  SEM of the
ratio of the phosphorylation of EGFR relative to the total unphos-
phosphorylated EGFR (n  6, **P  .01 compared to control).
Representative Western blots are shown above the graphs.sponse to ATF. Scrambled siRNA and siRNA againstADAM-12 had no effect (Fig 6). When the quantity of
HB-EGF released by ATF was measured in the presence of
the metalloprotease inhibitor, GM6001 and the ADAM
inhibitors, TAPI-0 and TAPI-1, there was a significant
reduction in the concentration of HB-EGF in the media
(Fig 6). This response was reproduced in the presence of
siRNA to ADAM-9 and ADAM-10; siRNA to ADAM-12,
and a scrambled control had no effect (Fig 6). When we
pre-incubated VSMC with siRNA to ADAM-9 and
ADAM-10 in the Boyden chamber, we saw a 70% decrease
inmigration compared to the scrambled siRNA and control
in response to ATF (Fig 6).
DISCUSSION
This study demonstrates that ATF requires EGFR for
cell migration and that this response is mediated by Gbg
G-proteins and by ADAM-9 and ADAM-10. ADAMs in
turn release the tethered ligand HB-EGF by a metallopro-
tease mediated process to activate EGF. This is distinct
from our published findings with the findings with the
intact molecule.6 Kalmes et al16 have shown that throm-
bin, another coagulation factor, will also mediate EGFR-
dependent VSMC migration and induce EGFR activation
through an extracellular pathway, which involves MMP-
mediated, HB-EGF release, and subsequent activation of
the EGFR. The EGFR/ErbB family is composed of four
receptor tyrosine kinases: ERB1/EGFR, ErbB2/neu,
ErbB3, and ErbB4, each of which consists of a glycosylated
ligand binding domain, a single transmembrane domain
and a cytoplasmic tyrosine kinase domain.17,18 Eleven dif-
ferent ligands have been identified for this receptor family;
Fig 5. Amino-terminal (ATF) (10 nM) induced epidermal growth
factor receptor (EGFR) phosphorylation which was inhibited by the
matrix metalloprotease inhibitor (GM6001) and the A Disintegrin
AndMetalloproteinase Domains (ADAM) inhibitors (TAPI-0 and
TAPI-1). Values are the mean  SEM of the ratio of the phos-
phorylation of EGFR relative to the total unphosphosphorylated
EGFR (n  6, *P  .05 **P  .01 compared to control).
Representative Western blots are shown above the graphs.EGF, TGF-, amphoregulin, HB-EGF, betacellulin, epi-
n S
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 5 Bakken et al 1301regulin, epigen bind to activate EGFR/ErbB1; betacellu-
lin, and in some cases HB-EGF, activate ErbB4 in addition
to ErbB1. Neuregulins are ligands for ErbB3 and ErbB4.
Although no ligand for ErbB2 has been identified, it ap-
pears to act as a cofactor for ErbB1, ErbB3, and ErbB4
forming heterodimers with the respective receptors. These
heterodimers enhance and diversify downstream signal
transduction pathways. ErbB1 has been studied in VSMC
and is expressed in the injured vessel wall.19,20 In the rat
carotid injury model, blockade of EGF with an antibody
will reduce intimal hyperplasia development.21 In a murine
injury model, deletion of uPA reduced intimal hyperplasia
while deletion of PAI-1 enhanced intimal hyperplasia.22-25
Thus, EGFR and uPA both appear to be necessary for vessel
remodeling. All ErbB ligands are synthesized as transmem-
brane precursors and reside in a tethered fashion on the
extracellular membrane. They can then in turn be proteo-
Fig 6. A, Small interference ribonucleic acid (siRNA) to
ADAM-10 and ADAM-12 resulted in a 
50% decrease
Dulbecco’s modified Eagle’s medium (DMEM) contro
siRNA, ADAM-9, and ADAM-10 significantly reduce
response to ATF. Scrambled amino-terminal (ATF) siRN
with GM6001, TAPI-0 and TAPI-1 and siRNA to AD
epidermal growth factor (HB-EGF) release from smoot
ADAM-9 and ADAM-10 markedly decreased smooth m
Boyden chamber in response to ATF. Values are the mealytically cleaved to release biologically active soluble growthfactors, which act in an autocrine and/or paracrine manner.
HB-EGF is expressed in atherosclerotic lesions26,27 and in
restenotic lesions following angioplasty.28-30 The present
study examined HB-EGF as HB-EGF has been shown to
stimulate the growth andmigration of VSMC under appro-
priate conditions.29,31 Activation of HB-EGF requires that
it be cleaved from the membrane and also requires cell
surface heparan sulphate proteoglycans to act as a co-
receptors; HB-EGF binding to EGFR can be antagonized
in a dose-dependent manner by heparin.32 We saw a similar
inhibitory effect with heparin in this study. Our data
using CRM197 and antibodies against HB-EGF and
EGFR support the presence of the extracellular pathway
using HB-EGF.
Receptor transactivation is the process whereby activa-
tion of a given receptor activates a heterologous receptor.12
Both G-protein-coupled receptors and receptor-linked ty-
isintegrin And Metalloproteinase Domains (ADAM)-9,
heir respective ADAM protein expression compared to
crambled siRNA. This was specific. B, Incubation with
idermal growth factor receptor (EGFR) activation in
siRNA against ADAM-12 had no effect.C, Incubation
9 and ADAM-10 markedly decreased heparin binding
scle cells into the media. D, Incubation with siRNA to
e cells migration compared to scrambled siRNA in the
EM (n 6, * P .05, **P .01 compared to control).A D
in t
l or s
d ep
A and
AM-
h mu
usclrosine kinases can induce rapid phosphorylation of the
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reduced MAPK activation.12-14 At present, the TMPS
mechanism of GPCR-induced EGFR activation is a widely
accepted model of receptor-linked tyrosine kinases transac-
tivation.12 In this model, there is a sequence of three
transmembrane signaling events: GPCR activation fol-
lowed byMMP activation, and subsequent activation of the
EGFR by HB-EGF, or other latent ligands of the EGFR.
Several different MMPs have been identified with HB-EGF
release: ADAM-10, ADAM-12, ADAM-17 (TNF- con-
verting enzyme), and MMP3.33 Activation of these pro-
teases pathway has been shown to involve one or more of
the following signaling molecules: src, intracellular cal-
cium, and protein kinase C.12 An alternative mechanism
may be inactivation of protein tyrosine phosphatases due to
the generation of oxygen free radicals by the NAD(P)H
oxidase complex. In the current study, we have identified
both intracellular and extracellular components of transac-
tivation. Transmembrane molecules such as ADAM are
attractive molecules for the transmembrane portion of the
signaling pathway. ADAM are approximately 70 to 90 kDa
(mature proteins; the unprocessed precursors are about 20
kDa larger due to their prodomain). They feature a com-
mon modular ectodomain structure, encompassing a vari-
able stalk region; a cysteine-rich domain, a disintegrin domain
binding to integrin-class cell adhesion molecules and a Zn-
binding metalloprotease domain. ADAM-12, ADAM-9,
ADAM-10, and ADAM-17 have been reported to be in-
volved in the ectodomain shedding of pro-HB-EGF.34,35
We have shown that the VSMC express ADAM-9, ADAM-
10, and ADAM-12. Furthermore, we have identified that
the predominant pathways that lead to HB-EGF release are
ADAM-9 and ADAM-10 in these particular VSMC. Little
is known of the role of ADAM in atherogenesis and vessel
remodeling.
CONCLUSION
ATF requires EGFR activation during cell migration.
ATF induces transactivation of EGFR by an ADAM-
mediated, HB-EGF-dependent process. This is the first
description of crosstalk via ADAM between ATF and
EGFR in VSMC.
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